#USA #Tampa #PainTEQ #SI Joint Fusion #TRAQ™

PainTEQ Launches TRAQ™: A Game-Changer in SI Joint Fusion

PainTEQ, recognized as a leader in sacroiliac joint fusion technology, has officially introduced TRAQ™, a novel posterior approach that marks a significant advancement in surgical techniques for treating SI joint dysfunction. This new implant is designed not only to enhance bi-cortical fixation but to also do so via a minimally invasive method suitable for modern surgical practices.

Evolution from LINQ® to TRAQ™

TRAQ™ builds on the established foundation laid by PainTEQ's LINQ® system, amplifying the choices available to interventionalists and surgeons. This innovation incorporates bi-cortical fixation, allowing the surgical team to engage both the sacral and iliac cortices effectively through a mere one-inch incision.

Dwayne Polzer, Vice President of Research and Development at PainTEQ, emphasizes the intentional design of TRAQ™. He explains that the triangular barbs of the implant are crafted precisely to optimize stability. Engaging both anatomical surfaces where mechanical grip is most robust, TRAQ™ aims to provide optimal support for bony fusion and patient recovery.

Surgical Advantages and Insights from Experts

The device’s deployment is designed to be tissue-sparing, which significantly minimizes disruption during the procedure, allowing for a more straightforward surgical process. Dr. Timothy R. Deer of The Spine and Nerve Center of the Virginias, who performed the initial TRAQ™ surgery, noted that the device’s design is a remarkable evolution in posterior SI joint fusion. He illustrated how TRAQ™ stabilizes and secures the SI joint while reducing patient complications linked to more invasive approaches.

Clinical Evidence with TRAQTION Study

To ensure the clinical efficacy of TRAQ™, PainTEQ has initiated the TRAQTION study—a comprehensive, multicenter effort aimed at evaluating the safety and effectiveness of the new device in real-world conditions. This study, having received central IRB approval, is slated to enroll up to 100 participants across ten sites in the U.S., with detailed follow-up over 24 months. PainTEQ's commitment to gathering clinical data underscores its proactive approach to advancing the field of pain management and surgical treatment.

About PainTEQ

Founded in Tampa, Florida, PainTEQ, LLC is dedicated to improving surgical outcomes for patients suffering from SI joint dysfunction. The introduction of TRAQ™ reflects the company's relentless pursuit of innovative solutions in medical technology. With a strong portfolio that includes both LINQ® and TRAQ™, PainTEQ aims to provide healthcare professionals with diverse tools that adapt to various clinical needs.

For more detailed information regarding TRAQ™ and its applications in SI joint fusion, visit PainTEQ's official website at www.painteq.com.

Safety Information

It is essential to note that TRAQ™ is intended solely for SI joint fusion applications. Patients should be thoroughly evaluated for various contraindications such as active infections, specific bone diseases, and other health conditions to ensure eligibility for this procedure. As with all surgical interventions, there are risks involved, and patients should discuss these with their healthcare provider.

Conclusion

TRAQ™ signifies a notable progression in the landscape of sacroiliac joint fusion. With its innovative design focused on patient safety and efficacy, PainTEQ continues to lead the way in offering high-quality solutions for debilitating joint pain, promising better outcomes for both patients and practitioners alike.